Peter Honig is Senior Vice President and Head of Global Regulatory Affairs (GRA) and Group Head of Development China and Development Japan. This organization is responsible for ensuring regulatory efficiency, strategic acceleration, and compliance throughout a product’s life cycle and developing and implementing strategies to deliver on and advance Pfizer’s commitment to patient access. The organization is also responsible for clinical development capabilities in China and Japan, with accountability for the clinical aspects of Pfizer marketing authorization applications in-country.
Prior to joining Pfizer, Peter was Head of Global Regulatory Affairs, Patient Safety and Quality Assurance at AstraZeneca. Preceding his role with AstraZeneca, he served as Senior Vice President, Worldwide Regulatory Affairs and Product Safety at Merck Research Laboratories and held senior leadership positions with the U.S. Food and Drug Administration (FDA).
Peter has been the PhRMA representative to the International Conference on Harmonization (ICH) Steering Committee since 2002 and is the current co-chair of the ICH Global Cooperation Group and regions. He is the industry representative to the FDA Advisory Committee on Pharmaceutical Science and is the Associate Editor of Clinical Pharmacology and Therapeutics. He has a faculty appointment at the Uniformed Services University of the Health Sciences and is a past President of the American Society for Clinical Pharmacology and Therapeutics (ASCPT).
Peter earned his baccalaureate, medical, and public health degrees from Columbia University in New York. He completed postgraduate training at Northwestern Memorial Hospital, Northwestern University Medical School and is board-certified in internal medicine and clinical pharmacology. In addition, he has authored numerous peer viewed publications and book chapters.